FDA greenlights prodisc C Nova for two-level cervical disc replacement

Centinel Spine has received FDA approval for its prodisc C Nova cervical total disc replacement device for two-level use in the U.S. The device, which has been in clinical use internationally since 2009, features flat endplates with low-profile keels engineered to match specific vertebral anatomy — making it a tailored option for patients with varying cervical spine structures. It is currently available on a limited-release basis in the U.S.

This approval completes Centinel Spine's "Match-the-Disc" portfolio, which now includes three cervical devices — the prodisc C Nova, prodisc C Vivo, and prodisc C SK — all cleared for both one- and two-level use.

Key Takeaways:

• Three prodisc cervical devices are now FDA approved for both one- and two-level use
• The prodisc C Nova's flat endplates and low-profile keels are designed to accommodate differences in patient anatomy and disease progression
• The device has over 15 years of international clinical use prior to this expanded U.S. approval

Why it matters: Having multiple implant designs approved for two-level use gives surgeons greater flexibility to match devices to individual patient anatomy — potentially improving outcomes and broadening access to disc replacement as an alternative to fusion surgery.